Gastroenterology Research and Practice

Review Article

A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan

Table 2

Extracted information for meta-analyses.


Study ID, intervention, trial stage	Treatment		Change in weekly SBMs		SBMs within 24 hrs	Time to first SBMs		Change in weekly CSBMs
Study ID, intervention, trial stage	Treatment		Mean	SE	%	Mean	SE	Mean	SE

Fukudo 2019, linaclotide, III [7]	Placebo	88	1.48	0.32	48.30	24.67	3.15	0.78	0.23
Fukudo 2019, linaclotide, III [7]	Linaclotide 5 mg	91	4.02	0.31	72.80	6.71	3.35	2.46	0.23

Fukudo 2018, linaclotide, II [8]	Placebo	80	1.91	0.35^†	—	—	—	1.10	0.30^†
	Linaclotide 0.0625 mg	82	3.89	0.35^†	—	—	—	2.16	0.30^†
	Linaclotide 0.125 mg	71	3.11	0.35^†	—	—	—	2.23	0.30^†
	Linaclotide 0.25 mg	72	3.87	0.35^†	—	—	—	2.53	0.35^†
	Linaclotide 0.5 mg	76	3.85	0.35^†	—	—	—	2.48	0.35^†

Kumagai 2018, elobixibat, I [9]	Placebo	10	1.40	0.57^†	40.00	—	—	—	—
	Elobixibat 2.5 mg	10	5.90	0.92^†	100.00	—	—	—	—
	Elobixibat 5 mg	10	8.50	0.79^†	100.00	—	—	—	—
	Elobixibat 10 mg	10	9.20	1.49^†	100.00	—	—	—	—
	Elobixibat 15 mg	9	9.50	1.43^†	100.00	—	—	—	—
	Elobixibat 20 mg	9	14.70	1.23^†	88.90	—	—	—	—

Nakajima 2018a, elobixibat, III [10]	Placebo	63	1.70	0.20	41.00	25.50	11.63	0.60^†	0.20^†
Nakajima 2018a, elobixibat, III [10]	Elobixibat 10 mg	69	6.40	0.60	86.00	5.10	1.80	3.30^†	0.50^†

Nakajima 2018b, elobixibat, II [11]	Placebo	40	2.60	0.46^†	48.00	36.20	5.72^†	1.50	0.22^†
	Elobixibat 5 mg	43	3.50	0.55^†	61.00	19.90	3.03^†	2.00	0.32^†
	Elobixibat 10 mg	39	5.70	0.67^†	90.00	8.20	1.31^†	3.40	0.58^†
	Elobixibat 15 mg	41	5.60	0.55^†	93.00	8.50	1.33^†	3.80	0.55^†

Fukudo 2015, lubiprostone, III [6]	Placebo	62	1.26	0.23	30.60	48.03	10.83^†	—	—
Fukudo 2015, lubiprostone, III [6]	Lubiprostone 48 μg	62	3.66	0.36	58.10	23.53	3.33^†	—	—

Fukudo 2011, lubiprostone, II [5]	Placebo	42	1.50	0.40	26.20	—	—	—	—
	Lubiprostone 16 μg	41	2.30	0.40	53.70	—	—	—	—
	Lubiprostone 32 μg	43	3.50	0.50	53.50	—	—	—	—
	Lubiprostone 48 μg	44	6.80	1.10	75.00	—	—	—	—

Kasugai 2019, lactulose, II [12]	Placebo	62	2.05	0.28^†	35.50	27.98	5.92	—	—
	Lactulose 13 g	63	2.17	0.26^†	47.60	24.50	3.36	—	—
	Lactulose 26 g	63	3.77	0.38^†	65.10	10.00	2.73	—	—
	Lactulose 39 g	62	5.05	0.65^†	67.70	10.33	4.28	—	—

CI: confidence interval; CSBM: complete spontaneous bowel movement; hrs: hours; SBM: spontaneous bowel movement. If SEs were not reported, they were calculated from SDs or 95% CIs. ^†Obtained from figures.